These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 12899660)

  • 41. Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxabicyclo[3.2.1]octanyl moiety.
    Chauret N; Nicoll-Griffith D; Friesen R; Li C; Trimble L; Dubé D; Fortin R; Girard Y; Yergey J
    Drug Metab Dispos; 1995 Dec; 23(12):1325-34. PubMed ID: 8689939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
    Knillová J; Bouchal J; Hlobilková A; Strnad M; Kolár Z
    Neoplasma; 2004; 51(5):358-67. PubMed ID: 15640940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes.
    Abass K; Reponen P; Turpeinen M; Jalonen J; Pelkonen O
    Drug Metab Dispos; 2007 Sep; 35(9):1634-41. PubMed ID: 17576805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
    Wang D; de la Fuente C; Deng L; Wang L; Zilberman I; Eadie C; Healey M; Stein D; Denny T; Harrison LE; Meijer L; Kashanchi F
    J Virol; 2001 Aug; 75(16):7266-79. PubMed ID: 11461999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A method for the study of N-glucosidation in vitro--amobarbital-N-glucoside formation in incubations with human liver.
    Tang BK; Carro-Ciampi G
    Biochem Pharmacol; 1980 Jul; 29(14):2085-8. PubMed ID: 7406923
    [No Abstract]   [Full Text] [Related]  

  • 46. Discovery of estrogen sulfotransferase inhibitors from a purine library screen.
    Verdugo DE; Cancilla MT; Ge X; Gray NS; Chang YT; Schultz PG; Negishi M; Leary JA; Bertozzi CR
    J Med Chem; 2001 Aug; 44(17):2683-6. PubMed ID: 11495578
    [No Abstract]   [Full Text] [Related]  

  • 47. N-Glucosidation of amobarbital in the cat.
    Carro-Ciampi G; Jurima M; Kadar D; Tang BK; Kalow W
    Can J Physiol Pharmacol; 1985 Oct; 63(10):1263-6. PubMed ID: 4075251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary structural requirements for N-glycosylation of peptides in rat liver.
    Bause E; Hettkamp H
    FEBS Lett; 1979 Dec; 108(2):341-4. PubMed ID: 520572
    [No Abstract]   [Full Text] [Related]  

  • 49. The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.
    Hassan M; Sallam H; Hassan Z
    Sultan Qaboos Univ Med J; 2011 May; 11(2):165-78. PubMed ID: 21969887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
    Trávnícek Z; Krystof V; Sipl M
    J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes.
    Cervenková K; Belejová M; Chmela Z; Rypka M; Riegrová D; Michnová K; Michalíková K; Súrová I; Brejcha A; Hanus J; Cerný B; Fuksová K; Havlícek L; Veselý J
    Physiol Res; 2003; 52(4):467-74. PubMed ID: 12899660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route.
    Chmela Z; Veselý J; Lemr K; Rypka M; Hanus J; Havlícek L; Krystof V; Michnová L; Fuksová K; Lukes J
    Drug Metab Dispos; 2001 Mar; 29(3):326-34. PubMed ID: 11181503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes.
    Rypka M; Veselý J; Chmela Z; Riegrová D; Cervenková K; Havlícek L; Lemr K; Hanus J; Cerný B; Lukes J; Michalíková K
    Xenobiotica; 2002 Nov; 32(11):1017-31. PubMed ID: 12487731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
    Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and biological activity of olomoucine II.
    Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.